BTK-Inhibition Enhances TLR-7-Mediated Interferon-Alpha Production in pDCs by Blocking the Inhibitory BDCA-2 Pathway

Area of Science:

• Immunology
• Pharmacology

Background:

• Plasmacytoid dendritic cells (pDCs) are key producers of type I interferons (IFN-α).
• Bruton's tyrosine kinase (BTK) is a critical signaling molecule in B cells and pDCs.
• BTK inhibitors (BTKi) are investigated for autoimmune diseases like Systemic Lupus Erythematosus (SLE) and Multiple Sclerosis (MS).

Purpose of the Study:

• To investigate the differential effects of BTK-inhibition (BTKi) on IFN-α production by pDCs stimulated via Toll-like receptor 9 (TLR-9) and TLR-7.
• To elucidate the mechanisms underlying BTKi's impact on pDC function, particularly concerning the BDCA-2 pathway.

Main Methods:

• pDCs were stimulated with TLR-9 and TLR-7 agonists in the presence or absence of BTKi.
• IFN-α production was measured.
• The role of the BDCA-2 pathway in BTKi's effects was assessed.

Main Results:

• BTKi completely blocked IFN-α production induced by TLR-9 stimulation.
• BTKi did not block, but rather enhanced, IFN-α production induced by TLR-7 stimulation.
• This enhancement was mediated by the blockade of the inhibitory BDCA-2 pathway.

Conclusions:

• BTKi exhibits differential effects on pDC IFN-α production depending on the TLR-stimulation pathway.
• The enhancement of IFN-α via TLR-7 by BTKi, due to BDCA-2 pathway inhibition, may contribute to the limited efficacy of BTKi in SLE.
• These findings hold significance for the strategic use of BTKi in ongoing clinical trials for MS.